References
- Akiyama, M. J., Cleland, C. M., Lizcano, J. A., Cherutich, P., & Kurth, A. E. (2019). Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: A retrospective cohort study. The Lancet Infectious Diseases, 19(11), 1255–1263. doi: https://doi.org/10.1016/S1473-3099(19)30264-6. Epub 2019 Sep 17.
- Akiyama, M. J., Norton, B. L., Arnsten, J. H., Agyemang, L., Heo, M., & Litwin, A. H. (2019). Intensive models of hepatitis C care for people Who inject drugs receiving opioid agonist therapy: A randomized controlled trial. Annals of Internal Medicine, 170(9), 594–603. https://doi.org/https://doi.org/10.7326/M18-1715
- Assefa, Y., Hill, P. S., Ulikpan, A., & Williams, O. D. (2017). Access to medicines and hepatitis C in Africa: Can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Globalization and Health, 13(1), 73. https://doi.org/https://doi.org/10.1186/s12992-017-0297-6
- Barocas, J. A., Brennan, M. B., Hull, S. J., Stokes, S., Fangman, J. J., & Westergaard, R. P. (2014). Barriers and facilitators of hepatitis C screening among people who inject drugs: A multi-city, mixed-methods study. Harm Reduction Journal, 11(1), 1. https://doi.org/https://doi.org/10.1186/1477-7517-11-1
- Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A. S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M. H., Negro, F., & Abaalkhail, F. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology & Hepatology, 2(3), 161–176. https://doi.org/https://doi.org/10.1016/S2468-1253(16)30181-9
- Boyzatis, R. (1998). Transforming qualitative information: Thematic analysis and code development. Sage Publications.
- Butner, J. L., Gupta, N., Fabian, C., Henry, S., Shi, J. M., & Tetrault, J. M. (2017). Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal of Substance Abuse Treatment, 75, 49–53. https://doi.org/https://doi.org/10.1016/j.jsat.2016.12.014
- Calabrese, S. K., Martin, S., Wolters, P. L., Toledo-Tamula, M. A., Brennan, T. L., & Wood, L. V. (2012). Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care, 24(9), 1092–1096. https://doi.org/https://doi.org/10.1080/09540121.2012.699670
- Caven, M., Malaguti, A., Robinson, E., Fletcher, E., & Dillon, J. F. (2019). Impact of hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. International Journal of Drug Policy, 72, 169–176. https://doi.org/https://doi.org/10.1016/j.drugpo.2019.05.011
- Chikovani, I., Ompad, D. C., Uchaneishvili, M., Sulaberidze, L., Sikharulidze, K., Hagan, H., & Van Devanter, N. L. (2019). On the way to hepatitis C elimination in the Republic of Georgia-barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. PLoS One, 14(4), e0216123. https://doi.org/https://doi.org/10.1371/journal.pone.0216123
- Chun, B. C. (2016). Understanding and modeling the super-spreading events of the Middle East respiratory syndrome outbreak in Korea. Infection & Chemotherapy, 48(2), 147–149. https://doi.org/https://doi.org/10.3947/ic.2016.48.2.147
- Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 20(1), 37–44. https://doi.org/https://doi.org/10.1177/001316446002000104
- Crowley, D., Van Hout, M. C., Lambert, J. S., Kelly, E., Murphy, C., & Cullen, W. (2018). Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners’ perspective. Harm Reduction Journal, 15(1), 62. https://doi.org/https://doi.org/10.1186/s12954-018-0269-z
- Douglass, C. H., Pedrana, A., Lazarus, J. V., FM‘t Hoen, E., Hammad, R., Leite, R. B., Hill, A., & Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Medicine, 16(1), 175. https://doi.org/https://doi.org/10.1186/s12916-018-1162-z
- Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017). Oral direct-acting Agent therapy for hepatitis C virus infection: A systematic review. Annals of Internal Medicine, 166(9), 637–648. https://doi.org/https://doi.org/10.7326/M16-2575
- Ford, N., Wiktor, S., Kaplan, K., Andrieux-Meyer, I., Hill, A., Radhakrishnan, P., Londeix, P., Forette, C., Momenghalibaf, A., Verster, A., & Swan, T. (2015). Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. International Journal of Drug Policy, 26(11), 1088–1093. https://doi.org/https://doi.org/10.1016/j.drugpo.2015.05.004
- Graham, C. S., & Swan, T. (2015). A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Research, 119, 89–96. https://doi.org/https://doi.org/10.1016/j.antiviral.2015.01.004
- Grebely, J., Hajarizadeh, B., Lazarus, J. V., Bruneau, J., Treloar, C., & International Network on Hepatitis in Substance Users. (2019). Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 72, 1–10. https://doi.org/https://doi.org/10.1016/j.drugpo.2019.07.016
- Harris, M., & Rhodes, T. (2013). Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal, 10(1), 7. https://doi.org/https://doi.org/10.1186/1477-7517-10-7
- Hickman, M., De Angelis, D., Vickerman, P., Hutchinson, S., & Martin, N. K. (2015). Hepatitis C virus treatment as prevention in people who inject drugs: Testing the evidence. Current Opinion in Infectious Diseases, 28(6), 576–582. https://doi.org/https://doi.org/10.1097/QCO.0000000000000216
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58(7), 928–936. https://doi.org/https://doi.org/10.1093/cid/ciu012
- Jaber, R., Braksmajer, A., & Trilling, J. S. (2006). Group visits: A qualitative review of current research. The Journal of the American Board of Family Medicine, 19(3), 276–290. https://doi.org/https://doi.org/10.3122/jabfm.19.3.276
- Jones, D. L., McPherson-Baker, S., Lydston, D., Camille, J., Brondolo, E., Tobin, J. N., & Weiss, S. M. (2007). Efficacy of a group medication adherence intervention among HIV positive women: The SMART/EST women's project. AIDS and Behavior, 11(1), 79–86. https://doi.org/https://doi.org/10.1007/s10461-006-9165-8
- Kurth, A. E., Cleland, C. M., Des Jarlais, D. C., Musyoki, H., Lizcano, J. A., Chhun, N., & Cherutich, P. (2015). HIV prevalence, estimated incidence, and risk behaviors Among people Who inject drugs in Kenya. Journal of Acquired Immune Deficiency Syndromes, 70(4), 420–427. https://doi.org/https://doi.org/10.1097/QAI.0000000000000769
- Lafferty, L., Wild, T. C., Rance, J., & Treloar, C. (2018). A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons. Harm Reduction Journal, 15(1), 39. https://doi.org/https://doi.org/10.1186/s12954-018-0246-6
- Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174. http://www.ncbi.nlm.nih.gov/pubmed/843571. https://doi.org/https://doi.org/10.2307/2529310
- Lee, S. S., Crofts, N., & Hung, C. C. (2019). Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs. International Journal of Infectious Diseases, 85, 141–142. https://doi.org/https://doi.org/10.1016/j.ijid.2019.06.003
- Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E., & Getz, W. M. (2005). Superspreading and the effect of individual variation on disease emergence. Nature, 438(7066), 355–359. https://doi.org/https://doi.org/10.1038/nature04153
- Lule, G. N., & Nyawira, B. (2017). Guidelines for the treatment of chronic hepatitis B and C viral infections in Kenya. http://publications.universalhealth2030.org/uploads/kenya-national-hepatitis-guidelines-2014.pdf. Access date can be listed as December 15, 2020.
- Martin, N. K., Thornton, A., Hickman, M., Sabin, C., Nelson, M., Cooke, G. S., Martin, T. C. S., Delpech, V., Ruf, M., Price, H., Azad, Y., Thomson, E. C., & Vickerman, P. (2016). Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clinical Infectious Diseases, 62(9), 1072–1080. https://doi.org/https://doi.org/10.1093/cid/ciw075
- Meehan, K. R., Hill, J. M., Root, L., Kimtis, E., Patchett, L., & Noffsinger, E. B. (2006). Group medical appointments: Organization and implementation in the bone marrow transplantation clinic. Supportive Cancer Therapy, 3(2), 84–90. https://doi.org/https://doi.org/10.3816/SCT.2006.n.003
- Morgan, J. R., Servidone, M., Easterbrook, P., & Linas, B. P. (2017). Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infectious Diseases, 17(Suppl 1), 697. https://doi.org/https://doi.org/10.1186/s12879-017-2779-9
- Nickbakhsh, S., & Leitch ECM, M. J. (2018). Evaluating “treatment as prevention” on the road to hepatitis C virus elimination. Annals of Blood, 3. https://doi.org/https://doi.org/10.21037/aob.2018.10.05
- Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., & Cacciapuoti, C. (2016). Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World Journal of Gastroenterology, 22(34), 7824–7840. https://doi.org/https://doi.org/10.3748/wjg.v22.i34.7824
- Pineiro, B., Diaz, D. R., Monsalve, L. M., Martinez, U., Meade, C. D., Meltzer, L. R., Brandon, K. O., Unrod, M., Brandon, T. H., & Simmons, V. N. (2018). Systematic transcreation of self-help smoking cessation materials for Hispanic/Latino smokers: Improving cultural relevance and acceptability. Journal of Health Communication, 23(4), 350–359. https://doi.org/https://doi.org/10.1080/10810730.2018.1448487
- Rao, D., Kekwaletswe, T. C., Hosek, S., Martinez, J., & Rodriguez, F. (2007). Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care, 19(1), 28–33. https://doi.org/https://doi.org/10.1080/09540120600652303
- Reid, S. R. (2009). Injection drug use, unsafe medical injections, and HIV in Africa: A systematic review. Harm Reduction Journal, 6(1), 24. https://doi.org/https://doi.org/10.1186/1477-7517-6-24
- Rich, Z. C., Chu, C., Mao, J., Zhou, K., Cai, W., Ma, Q., Volberding, P., & Tucker, J. D. (2016). Facilitators of HCV treatment adherence among people who inject drugs: A systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health, 16(1), 994. https://doi.org/https://doi.org/10.1186/s12889-016-3671-z
- Rosenthal, E. S., & Graham, C. S. (2016). Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer, 11(1), 24. https://doi.org/https://doi.org/10.1186/s13027-016-0071-z
- Ruta, S., & Cernescu, C. (2015). Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World Journal of Gastroenterology, 21(38), 10811–10823. https://doi.org/https://doi.org/10.3748/wjg.v21.i38.10811
- Scheibe, A., Young, K., Moses, L., Basson, R. L., Versfeld, A., Spearman, C. W., Sonderup, M. W., Prabdial-Sing, N., Manamela, J., Puren, A. J., Rebe, K., & Hausler, H. (2019). Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: Findings from a three-city cross-sectional survey. Harm Reduction Journal, 16(1), 28. https://doi.org/https://doi.org/10.1186/s12954-019-0298-2
- Stein, M. R., Soloway, I. J., Jefferson, K. S., Roose, R. J., Arnsten, J. H., & Litwin, A. H. (2012). Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment, 43(4), 424–432. https://doi.org/https://doi.org/10.1016/j.jsat.2012.08.007
- Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., Keaveney, M., Lambert, J., McCormick, P. A., McKiernan, S., Moloney, J., Perry, N., & Cullen, W. (2010). Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs, 24(12), 753–762. https://doi.org/https://doi.org/10.1089/apc.2010.0142
- Ti, L., Socias, M. E., Wood, E., Milloy, M. J., Nosova, E., DeBeck, K., Kerr, T., & Hayashi, K. (2018). The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One, 13(3), e0194162. https://doi.org/https://doi.org/10.1371/journal.pone.0194162
- Tong, A., Sainsbury, P., & Craig, J. (2007). Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 19(6), 349–357. https://doi.org/https://doi.org/10.1093/intqhc/mzm042
- Versfeld, A., McBride, A., Scheibe, A., & Spearman, C. W. (2020). Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Harm Reduction Journal, 17(1), 39. https://doi.org/https://doi.org/10.1186/s12954-020-00382-3
- Wang, Y., Tan, X. D., Zhou, C., Zhou, W., Peng, J. S., Ren, Y. S., Ni, Z. L., Liu, B., Yang, F., & Gao, X. D. (2016). Exploratory social network analysis and gene sequencing in people who inject drugs infected with hepatitis C virus. Epidemiology and Infection, 144(14), 3080–3090. https://doi.org/https://doi.org/10.1017/S0950268816001333
- Yap, L., Carruthers, S., Thompson, S., Cheng, W., Jones, J., Simpson, P., Richards, A., Thein, H. H., Haber, P., Lloyd, A., & Butler, T. (2014). A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One, 9(2), e87564. https://doi.org/https://doi.org/10.1371/journal.pone.0087564